OncoMatch/Clinical Trials/NCT06810791
HVA vs IA/DA or VA in the Treatment of ND HR-AML
Is NCT06810791 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including HVA and VA for newly diagnosed acute myeloid leukemia with high risk.
Treatment: HVA · VA · Standard Chemotherapy — The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed high-risk AML patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: anti-aml therapy
Exception: leukopenia therapy, such as hydroxyurea or cytarabine < 1.0g/d
Lab requirements
Kidney function
creatinine clearance acuity 30 ml/min
Liver function
alt < 5 times normal value, bilirubin < 3 times normal value
Cardiac function
cardiac function > level 2 [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06810791 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages